Nootropics Index - Save on smarter supplements
Nootropics>Hormones & endocrine-related compounds>Enclomiphene
Hormones & endocrine-related compounds

Enclomiphene

Enclomiphene citrate

Enclomiphene is the trans-isomer of clomiphene. Human studies in selected adult men evaluated endocrine markers including testosterone, LH, FSH, and sperm concentration. No trial in the reviewed source set assessed cognitive performance, so it provides no finding for focus, memory, learning, mood, or general productivity. The profile carries high caution because it changes the reproductive hormone axis, clomiphene-label safety information is class context rather than Enclomiphene-specific event rates, and sport or product-identity questions need independent verification.

Hormone SupportHormonal Axis RelatedClinical ResearchLimited Human EvidenceDose Dependent EvidenceForm Dependent EvidencePopulation Specific Evidence
Updated August 2026/6 min read/11 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What Enclomiphene is

1

This page describes Enclomiphene as the trans-isomeric component of clomiphene. It is represented in clinical endocrine studies and in online research-product listings, which are different evidence and supply contexts.

Human evidence is endocrine, not nootropic2
The reviewed human studies in selected adult men measured endocrine markers. They do not establish Enclomiphene as a memory, focus, learning, mood, or productivity compound.
Population boundary3
Phase III work enrolled overweight men with low testosterone and low or normal LH. It does not establish outcomes in healthy users or other populations.
How the evidence is used6
This page separates identity data, Enclomiphene clinical studies, clomiphene-label class context, WADA sport rules, and historical product-listing context. It does not substitute one source type for another.
02

Names, aliases and forms

Common NameEnclomiphene citrate
Spelling VariantEnclomifene
Chemical NameTrans-clomiphene
Brand NameAndroxal
Pubchem Cid1548953
Molecular FormulaC26H28ClNO
InchikeyGKIRPKYJQBWNGO-OCEACIFDSA-N
Iupac Name2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
03

Mechanisms of action

Endocrine feedback context

2

The phase II study assessed changes in testosterone, LH, and FSH after oral Enclomiphene. These laboratory effects provide endocrine context; they do not establish cognitive performance effects.

04

Potential effects and evidence map

Human Enclomiphene studies in selected adult men measured endocrine markers. Phase II and III work found increases in testosterone, LH, and FSH, while comparisons with testosterone gel also assessed sperm concentration. This population-specific endocrine evidence does not establish a cognitive, focus, memory, learning, or healthy-user performance effect. Clinical study doses and clomiphene-label safety information are context, not a consumer protocol or an Enclomiphene-specific safety-rate estimate.

Effect domainMagnitudeGrade
Libido / vitality2
CumulativeConfidence: Medium

No reliable libido or vitality outcome was established in the reviewed Enclomiphene trials.

Note Hormone-marker changes are not a controlled vitality outcome.

0/5
D
Physical energy / endurance2
UnknownConfidence: High

No direct energy, endurance, or performance outcome was established.

Note Reviewed Enclomiphene studies measured endocrine markers, not performance endpoints.

0/5
E
Mood / wellbeing2
UnknownConfidence: High

No reliable mood or wellbeing outcome was established.

Note Hormone-marker changes do not establish a mood effect.

0/5
E
Focus / attention2
UnknownConfidence: High

No reliable focus or attention benefit was established.

Note None of the reviewed Enclomiphene trials tested attention.

0/5
E
Memory / learning2
UnknownConfidence: High

No controlled memory or learning benefit was established.

Note None of the reviewed Enclomiphene trials tested memory or learning.

0/5
E
05

Typical dosages and timing

Phase II study26.25-25 mg/day

The phase II study evaluated 6.25 mg, 12.5 mg, and 25 mg daily. This is a controlled study context, not a self-use protocol or a validated consumer dose.

06

Timing & effect horizon

Effect horizonCumulative
Cumulative
Onset2Cumulative
2-6 weeks
Endocrine-marker observation window2

The phase II report describes testosterone and LH changes within two weeks and assessment after six weeks of daily study dosing. This does not predict an individual symptom response.

07

Safety, side effects and risk profile

Hormonal caution2
Confidence: High

Phase II work documented changes in testosterone, LH, and FSH, so the compound belongs in an endocrine and laboratory-monitoring context rather than a casual nootropic stack.

Note The direct human evidence is population-specific endocrine-marker evidence.

4/5
B
Legal / regulatory risk11
Confidence: High

WADA places clomifene in the 2026 S4.2 anti-estrogenic section and bars SERMs in sport at all times.

Note Sport rules are separate from medicine, import, prescription, or product-claim status.

4/5
A
Pregnancy / lactation caution9
Confidence: High

The current U.S. clomiphene citrate label contraindicates use during pregnancy; this is clomiphene-class context, not an Enclomiphene-specific outcome estimate.

Note Pregnancy and lactation questions require qualified medical review.

4/5
B
Headache / dizziness9
Confidence: Medium

The clomiphene citrate label reports visual symptoms including blurred vision, flashes, spots, scotomata, and photophobia; it does not provide an Enclomiphene-specific event rate.

Note Visual changes need prompt clinical evaluation.

3/5
B
Liver / kidney caution9
Confidence: Medium

The current U.S. clomiphene citrate label contraindicates use with liver disease or a history of liver dysfunction; that is class context, not an Enclomiphene-specific safety-rate estimate.

Note No broad Enclomiphene consumer hepatic-safety framework was identified.

3/5
B
Cardiovascular caution9
Confidence: Low

The reviewed Enclomiphene studies do not establish a consumer cardiovascular risk rate; clomiphene-label context cannot be converted into an Enclomiphene-specific estimate.

Note The caution reflects evidence limits rather than a quantified Enclomiphene harm rate.

2/5
D
Interaction risk9
Confidence: Low

No reviewed Enclomiphene interaction study established a safe consumer combination profile.

Note No individual combination can be judged safe from the cited evidence.

3/5
D
Evidence uncertainty6
Confidence: High

The evidence is limited to selected endocrine study populations; nootropic outcomes, long-term self-directed use, and market-product identity remain unresolved.

Note Benefits and risks must remain population- and source-specific.

4/5
C
Safety context2Endocrine monitoring

Direct human evidence shows changes in testosterone, LH, and FSH. Those changes make hormone and medication context important and are not comparable to an ordinary supplement effect.

Class warning9Visual changes

The current U.S. clomiphene citrate label reports blurred vision, spots, flashes, scotomata, photophobia, and other visual symptoms. This is class context and does not quantify an Enclomiphene-specific event rate.

Label scope9Clomiphene citrate

The current U.S. clomiphene citrate label contraindicates use during pregnancy and with liver disease or a history of liver dysfunction. It should not be read as an Enclomiphene-specific safety-rate estimate.

08

Interactions and cautions

Interaction evidence9

The reviewed source set did not identify an Enclomiphene interaction study that establishes a safe consumer combination profile. Hormone or medication changes need qualified clinical review rather than stack inference.

09

Legal and regulatory status

WADA 202611

For sport governed by the WADA 2026 Prohibited List, clomifene is named among anti-estrogenic substances and SERMs are prohibited at all times. This sport rule does not determine medicine, import, prescription, or product-claim status in any jurisdiction.

10

How it compares

Trial comparison3

In the reviewed phase III studies, both approaches raised testosterone. The trial report describes increased LH and FSH with Enclomiphene and reduced gonadotropins with testosterone gel; sperm concentration was also assessed in that comparison.

11

Practical buying and quality notes

  • The indexed legacy rows include solution and capsule presentations, but no active offer is currently mapped. Historical rows do not establish current availability, identity, concentration, purity, or product quality.
  • The profile has no mapped active offer or current batch record. It therefore makes no claim about a seller, concentration, isomer ratio, assay, contamination testing, storage, or legal route.
12

FAQ

Is Enclomiphene a nootropic?

2

No reliable focus, memory, learning, mood, or productivity outcome was established in the reviewed human Enclomiphene studies. Their measured outcomes were endocrine markers.

What dose did Enclomiphene studies use?

2

The phase II study evaluated 6.25 mg, 12.5 mg, and 25 mg daily in its selected participants. Study dosing is not a validated consumer dose or self-use instruction.

When were hormone markers assessed?

2

The phase II report describes changes within two weeks and detailed assessment after six weeks of daily study dosing. It does not predict individual symptoms or a general nootropic response.

Is Enclomiphene permitted in sport?

11

For sport governed by WADA, the 2026 list names clomifene among anti-estrogenic substances and prohibits SERMs at all times. A vendor label does not settle anti-doping status.

Who needs additional caution?

9

The cited label context and missing Enclomiphene-specific self-use evidence make pregnancy, liver disease or history of liver dysfunction, sport-tested activity, hormone or medication changes, and uncertain product identity especially unsuitable for casual experimentation.

13

References

  1. PubChem. Enclomiphene (CID 1548953). Accessed 2026-07-01.
  2. Wiehle RD, et al. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. BJU Int. 2013.
  3. Kim ED, et al. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU Int. 2016.
  4. Wiehle RD, et al. Oral enclomiphene citrate stimulates endogenous testosterone and sperm counts in men with low testosterone. J Sex Med. 2013.
  5. Giagulli VA, et al. Selective modulation of estrogen receptor in obese men with androgen deficiency: a systematic review and meta-analysis. Andrology. 2023.
  6. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025.
  7. ClinicalTrials.gov. NCT01619683, Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism. Accessed 2026-07-01.
  8. ClinicalTrials.gov. NCT01739582, Extension Study of Enclomiphene Citrate in Men With Secondary Hypogonadism. Accessed 2026-07-01.
  9. DailyMed. Clomiphene citrate tablet label, Acetris Pharma Holdings, LLC. Published Jun 30, 2026.
  10. DailyMed. CLOMID (clomiphene citrate) tablet label, Cosette Pharmaceuticals, Inc. Published Feb 03, 2025.
  11. World Anti-Doping Agency. The 2026 Prohibited List. Effective 2026.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.